Disseminated intravascular coagulation: Testing and diagnosis

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 130-134

  Wada, Hideo ^a   Matsumoto, Takeshi ^b   Yamashita, Yoshiki ^c   Hatada, Tsuyoshi ^b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnostic criteria; DIC; Hemostatic abnormality; Mortality; Treatment

Indexed keywords

FIBRINOGEN; LIPOCORTIN 2; PLASMINOGEN ACTIVATOR; THROMBOPLASTIN;

ASYMPTOMATIC DISEASE; BLEEDING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT INDICATION; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; PHYSIOPATHOLOGY; PROGNOSIS;

DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; PROGNOSIS;

EID: 84901987966     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.04.020     Document Type: Review

References (55)

1. Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004, 344:13-21.
2. Wada H., Matsumoto T., Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 2012, 5:643-652.
3. Colman R.T., Robby S.J., Minna J.D. Disseminated intravascular coagulation (DIC): an approach. Am J Med 1974, 52:679-689.
4. Al-Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb Diath Haemorrh 1975, 34:181-193.
5. Siegal T., Seligsohn U., Aghai E., Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost 1978, 39:122-134.
6. Spero J.A., Lewis J.H., Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost 1980, 43:28-33.
7. Aoki N., Hasegawa H. About revised version of "Auxiliary test findings and results for diagnostic ". Diagnostic criteria for DIC: a study report by the research committee on blood coagulation on abnormalities in 1987. Special diseases designated by Japanese Ministry of Health and Welfare 1988, 37-41.
8. Taylor F.B., Toh C.H., Hoots W.K., Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-on behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001, 86:1327-1330.
9. Wada H., Thachil J., Di Nisio M., et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis: guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013, 11:761-767.
10. Warren B.L., Eid A., Singer P., et al. High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA 2001, 286:1869-1878.
11. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med 2001, 8:699-709.
12. Ranieri V.M., Thompson B.T., Barie P.S., et al. PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064.
13. Abraham E., Reinhart K., Opal S., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
14. Aoki N., Matsuda T., Saito H., et al. A comparative double blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 2002, 75:540-547.
15. Saito H., Maruyama I., Shimazaki S., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123)in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41.
16. Müller-Berghause G., Blombäck M., ten Cate J.W. Attempts to Define Disseminated Intravascular Coagulation. DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation 1993, 3-8. Elsevier Science Publishers B.V, Amsterdam. G. Müller-Berghause, M. Blombäck, K. Madlener, J.W. ten Cate (Eds.).
17. Müller-Berghaus G., ten Cate H., Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 2001, 86:1327-1330.
18. Kushimoto S., Wada H., Kawasugi K., et al. Increased ratio of soluble fibrin formation/thrombin generation in patients with DIC. Clin Appl Thromb Hemost 2012, 18:627-631.
19. Seki Y., Wada H., Kawasugi K., et al. Japanese Society of Thrombosis Hemostasis/DIC Subcommittee A prospective analysis of disseminated intravascular coagulation in patients with infections. Intern Med 2013, 52:1893-1898.
20. Wada H., Tamaki S., Tanigawa M., et al. Plasma level of IL-1β in disseminated intravascular coagulation. Thromb Haemost 1991, 65:364-368.
21. Wada H., Ohiwa M., Kaneko T., et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am J Hematol 1991, 37:147-151.
22. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
23. Fuchs T.A., Brill A., Duerschmied D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 107:15880-15885.
24. Massberg S., Grahl L., von Bruehl M.L., et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010, 16:887-896.
25. Hatada T., Wada H., Nobori T., et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005, 94:975-979.
26. Wada H., Minamikawa K., Wakita Y., et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993, 43:190-194.
27. Wada H., Hatada T., Okamoto K., et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 2010, 85:691-694.
28. Wada H., Wakita Y., Nakase T., et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995, 74:848-852.
29. Wada H., Asakura H., Okamoto K., et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010, 125:6-11.
30. Kawasugi K., Wada H., Hatada T., et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res 2011, 128:186-190.
31. Yamashita Y., Wada H., Nomura H., et al. Elevated fibrin-related markers in patients with malignant diseases frequently associated with disseminated intravascular coagulation and venous thromboembolism. Intern Med 2014, 53:413-419.
32. Wada H., Nagano T., Tomeoku M., et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1982, 30:315-322.
33. Wada H., Kumeda Y., Ogasawara Z., et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol 1993, 42:166-170.
34. Wojtukiewicz M.Z., Sierko E., Zacharski L.R., Zimnoch L., Kudryk B., Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003, 29:291-300.
35. Gheldof D., Mullier F., Bailly N., et al. Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thromb Res 2014, 133:433-439.
36. Sase T., Wada H., Nishioka J., et al. Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. Thromb Haemost 2003, 89:660-665.
37. Sase T., Wada H., Kamikura Y., et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 2004, 92:132-139.
38. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia. Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-4302.
39. Tallman M.S., Lefèbvre P., Baine R.M., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004, 2:1341-1350.
40. Iba T., Saito D., Wada H., Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133.
41. Yamashita Y., Naitoh K., Wada H., et al. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb Res 2014, 133:440-444.
42. Habe K., Wada H., Ito-Habe N., et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012, 129:598-602.
43. Bone R.C. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 1992, 268:3452-3455.
44. Gando S., Iba T., Eguchi Y., et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631.
45. Gando S., Wada H., Asakura H., et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005, 11:71-76.
46. Takemitsu T., Wada H., Hatada T., et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011, 105:40-44.
47. Toh C.H., Hoots W.K. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007, 5:604-606.
48. Hayakawa M., Gando S., Hoshino H. A prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost 2007, 13:172-181.
49. Egi M., Morimatsu H., Wiedermann C.J., et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb Haemost 2009, 101:696-705.
50. Toh C.H., Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2005, 16:69-74.
51. Wada H., Hatada T., Okamoto K., et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 2010, 85:691-694.
52. Polderman K.H., Girbes A.R.J. Drug intervention trials in sepsis: divergent results. Lancet 2004, 363:1721-1723.
53. Minneci P.C., Dean K.J., Cui X., Banks S.M., Natanson C., Eichacker P.Q. Antithrombotic therapies for severe sepsis: a need for more studies. Crit Care Med 2006, 34:538-541.
54. Kienast J., Juers M., Wiedermann C.J., et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97.
55. Gando S., Saitoh D., Ogura H., et al. for Japanese Association for Acute Medicine Sepsis Registry Study Group. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 2013, 17:R111.